

Remplir™ Humanitarian Success in Ukraine Drives Expanded Support for Victims of War

- **Growing use of Remplir™** in the treatment of severe peripheral nerve injuries sustained during the ongoing conflict in Ukraine, with surgeons reporting strong clinical utility in managing complex trauma cases.
- **Remplir offers several unique advantages**, including patented technology that creates a bioactive healing chamber to support tissue regeneration and integration, while providing a faster, easier surgical procedure and reducing or eliminating the need for sutures.
- **Remplir's global humanitarian program has expanded**, with additional devices now being shipped to Ukraine through a coordinated philanthropic initiative following the success of the initial humanitarian deployment in April 2025.
- **The additional shipment will support the treatment of complex battlefield and civilian trauma injuries**, further increasing access to advanced nerve repair technology for victims of war.
- **The Humanitarian shipment has been supported by leading Australian corporate donors**, including Wyllie Group, Andrew Forrest's Minderoo Foundation, Canaccord Genuity Australia, Gilbert + Tobin, Device Technologies Australia, Bell Potter and Argonaut Securities.
- **Clinical experience gained through real-world use in Ukraine** is expected to support surgeon education and the initial commercial launch following anticipated regulatory clearance in the European Union and United Kingdom in 2H CY2026.

Perth, Australia; 30 June 2026: Regenerative medicine company Orthocell Limited (ASX: OCC, "Orthocell" or the "Company") is pleased to announce it has extended the global reach of its FDA-cleared collagen medical device Remplir™ to Ukraine as part of a coordinated philanthropic initiative to provide medical aid to victims of war.

Orthocell first delivered an initial humanitarian shipment of Remplir to Ukraine in April 2025. The shipment was coordinated through Professor Fiona Wood AO and UK defence surgeons supporting battlefield trauma programs.

More Remplir devices are now in transit to Ukraine after a group of Australian corporate donors - including Wyllie Group, Andrew Forrest's Minderoo Foundation, Canaccord Genuity Australia, Gilbert + Tobin, Device Technologies Australia, Bell Potter, and Argonaut Securities - agreed to purchase 100 devices at humanitarian pricing to ship to Ukraine. Orthocell has also donated a further 100 devices and the Ukraine Crisis Appeal has pledged AUD \$10K to support this effort.



Current estimates indicate more than 400,000 Ukrainians including children have sustained trauma-related injuries during the conflict, creating substantial ongoing demand for advanced reconstructive and nerve repair technologies for victims of war and veterans.

The Ukraine Crisis Appeal is now welcoming donations to bring more Remplir devices and other urgent medical supplies to victims of war. To donate visit ukrainecrisisappeal.org and scroll to the “Nerve Repair for Ukraine” campaign.

Orthocell CEO and Managing Director Paul Anderson said “Feedback from surgeons about the clinical utility of Remplir in practice has been extremely positive.

“Remplir devices have already been used in the treatment of several severe trauma injuries sustained during the ongoing conflict in Ukraine, including peripheral nerve injuries associated with amputations, blast trauma, and nerve crush injuries.

“In addition to supporting ongoing humanitarian aid, in partnership with The Ukraine Crisis Appeal, Orthocell is supporting peer-to-peer training between leading surgeons across international borders. This was anchored by a recent Nerve Symposium event in Sydney Australia to advance knowledge-sharing in reconstructive surgery, peripheral nerve repair, and trauma management.”

Remplir is redefining the global standard of care for nerve repair procedures, by unlocking the power of the human body to heal. Remplir is made from pure collagen and in clinical practice creates a bioactive healing chamber to support new tissue formation and integration. By comparison, suturing nerves can place delicate tissue under tension, causing scarring, fibrosis and neuroma formation.

Remplir is highly regarded by surgeons for its versatility and ease of use. It is used to connect severed nerves following trauma, protect repaired or decompressed nerves after injury or surgery, and cap nerve endings following amputations or other procedures to support improved patient outcomes.

Remplir was cleared by the US FDA in April 2025 – the largest healthcare market in the world. It is also cleared for use and sale in Australia, New Zealand, Canada, Singapore, Thailand, and Hong Kong. Other jurisdictions are imminent too, with regulatory approval for the European Union (EU) and United Kingdom (UK) expected in late 2026.

Release authorised by:
Paul Anderson
Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited
CEO and MD

P: +61 8 9360 2888

E: paul.anderson@orthocell.com

Media enquiries

Haley Chartres
H^ACK Director

P: +61 423 139 163

E: haley@hck.digital

Investor enquiries

Shaun Duffy
VECTOR Advisors

P: +61 404 094 384

E: sduffy@vectoradvisors.au

About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.